In a re­peat set­back, Neu­ro­crine flags a fail­ure for Tourette syn­drome study — shares sink

Shares of Neu­ro­crine $NBIX got ham­mered Tues­day morn­ing af­ter the biotech con­ced­ed that its Phase IIb study of val­be­nazine for Tourette syn­drome had flopped.

The stock swift­ly plunged more than 20% on the news.

The pri­ma­ry end­point for their study was a re­duc­tion in fa­cial tics among pa­tients with the dis­ease. We’re not get­ting to see the ac­tu­al da­ta yet to see just how bad a set­back this is.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.